1x10^6 mouse bone marrow cells were surface stained with 0.25 ug FITC Plus Anti-Mouse CD11b (M1/70) (FITC-65055, Clone:M1/70), and 0.25 ug APC Anti-Mouse Ly-6G/Ly-6C (Gr-1) (RB6-8C5) (APC-65140, Clone: RB6-8C5), and 0.25 ug FITC Plus Rat IgG2b Isotype Control (LTF-2) (FITC-65211, Clone: LTF-2). Cells were not fixed.
1x10^6 human PBMCs were surface stained with 5ul FITC Plus Anti-Human Endoglin/CD105 Rabbit Recombinant Antibody (FITC-98013, Clone: 230047E5) (red), or 0.25 ug Isotype Control (blue). Cells were incubated with FC Receptor Block prior to staining. Cells were not fixed. Monocytes were gated.
1x10^6 Balb/c mouse peritoneal macrophages were surface stained with 0.5 ug FITC Plus Anti-Mouse CD80 (B7-1) (16-10A1) (FITC-65076, Clone: 16-10A1) (red), or 0.5 ug FITC Armenian Hamster IgG Isotype Control (PIP) (FITC-65210, Clone: PIP) (blue). Cells were not fixed.
1X10^6 C57BL/6 mouse splenocytes were surface stained with CoraLite® Plus 647 Anti-Mouse CD4 (GK1.5) and 0.5 ug FITC Anti-Mouse CD3ε (FITC-65060, Clone:145-2C11) or 0.5 ug FITC Armenian Hamster IgG Isotype Control (PIP). Cells were not fixed.
1X10^6 mouse splenocytes were surface stained with CoraLite® Plus 647 Anti-Mouse CD3 (17A2) (CL647-65077, Clone: 17A2) and 0.5 ug FITC Plus Anti-Mouse CD4 (FITC-65104, Clone: GK1.5) or 0.5 ug FITC Plus rat IgG2b isotype control. Cells were not fixed.
1X10^6 untreated or LPS-treated mouse splenocytes were surface stained with 0.125 ug FITC Plus Anti-Mouse CD86 (FITC-65068, Clone: GL1). Cells were not fixed.
1X10^6 LPS treated mouse splenocytes were surface stained with 0.125 ug FITC Plus Anti-Mouse CD86 (FITC-65068, Clone: GL1) (red) or 0.125 ug FITC-rat IgG2a isotype control. Cells were not fixed.
1X10^6 mouse splenocytes were surface stained with APC Anti-Mouse CD4 (GK1.5) (APC-65104, Clone: GK1.5) and 1 ug FITC Plus Anti-Mouse CD3 (FITC-65077, Clone: 17A2) or 1 ug isotype control. Cells were not fixed.
100 ul human peripheral blood were surface stained with 20.00 ul FITC Anti-Human CD34 (FITC-65183, Clone: QBEnd-10) and then treated with red blood cell lysis buffer. Cells were not fixed.
Human monocyte-derived dendritic cells (monocytes stimulated with GM-CSF and IL-4) were surface stained with 4 ul FITC Anti-Human CD206 (FITC-65155, Clone: 15-2) (green) or FITC-Mouse IgG1 isotype control (black). Cells were not fixed.
1X10^6 C57BL/6 mouse splenocytes were surface stained with APC-Anti-Mouse CD3ε (APC-65060, Clone: 145-2C11) and 0.25 ug FITC-Rat IgG2b isotype control (left) or 0.25 ug FITC Anti-Mouse CD16 / CD32 (FITC-65080, Clone: 2.4G2) (right). Cells were not fixed.
1X10^6 C57BL/6 mouse bone marrow cells were surface co-stained with APC Anti-Mouse CD45R (B220) and 0.5 ug FITC Plus Anti-Mouse CD31 (FITC-65058, Clone: 390) or 0.5 ug FITC Rat IgG2a Isotype Control (2A3) (FITC-65209, Clone: 2A3). Cells were not fixed.
Immunofluorescent analysis of (4% PFA) fixed bEnd.3 cells using FITC Anti-Mouse CD31 (FITC-65058, Clone: 390) at dilution of 1:100.
1X10^6 human PBMCs were surface stained with 5 ul FITC Plus Anti-Human CD44 (FITC-65063, Clone: F10-44-2), or Mouse IgG2a Isotype Control. Cells were not fixed. Lymphocytes were gated.
1X10^6 human PBMCs were surface stained with 5 ul FITC Anti-Human CD45 (FITC-65109, Clone:HI30) (red) or Mouse IgG1 Isotype Control. Cells were not fixed. Lymphocytes were gated.
1X10^6 mouse splenocytes were surface stained with APC Anti-Mouse MHC Class II (I-A/I-E) (APC-65122, Clone: M5/114.15.2) and 0.25 ug FITC Plus Anti-Mouse CD11c (FITC-65130, Clone: N418) or 0.25 ug FITC Plus Hamster IgG isotype control. Cells were not fixed.
1X10^6 mouse splenocytes were surface stained with 5 ul CoraLite® Plus 647 Anti-Mouse CD4 (CL647-65104, Clone: GK1.5) and 0.5 ug FITC Plus Rat IgG2a isotype control (left) or 0.5 ug FITC Plus Anti-Mouse CD8a (FITC-65069, Clone: 53-6.7) (right). Cells were not fixed.
1X10^6 BALB/c mouse splenocytes were surface stained with APC-Anti-Mouse CD3ε (APC-65060, Clone: 145-2C11) and 0.20 ug FITC-Anti-Mouse CD40 (FITC-65062, Clone: 1C10). Cells were not fixed.
1X10^6 BALB/c mouse splenocytes were surface stained with APC-Anti-Mouse CD3ε (APC-65060, Clone: 145-2C11) and 0.20 ug FITC-Rat IgG2a isotype control antibody. Cells were not fixed.
1X10^6 mouse splenocytes were surface stained with CoraLite® Plus 647 Anti-Mouse CD4 (GK1.5) (CL647-65104, Clone: GK1.5) and 0.13 ug FITC Plus Rat IgG1 isotype control (left) or 0.13 ug FITC Plus Anti-Mouse CD25 (FITC-65137, Clone: PC61.5) (right). Cells were not fixed.
1X10^6 mouse splenocytes were surface co-stained with Anti-Mouse CD3 and 0.5 ug FITC Anti-Mouse CD44 (FITC-65117, Clone:IM7) or 0.5 ug Control Antibody. Cells were not fixed.
1X10^6 mouse splenocytes were surface co-stained with Anti-Mouse CD3ε and 0.25 ug FITC Anti-Mouse CD90.2 (FITC-65088, Clone:30-H12) or 0.25 ug Control Antibody. Cells were not fixed.
1X10^6 mouse bone marrow cells were surface stained with 0.5 ug FITC Plus Anti-Mouse Ly-6G/Ly-6C (Gr-1) (FITC-65140, Clone: RB6-8C5) or 0.5 ug isotype control. Cells were not fixed.